IDPH COVID-19 Guidance
Home Quarantine Guidance for Close Contacts to Coronavirus Disease 2019 (COVID-19) Cases
These quarantine instructions are for people who live in the same household or have had close contact with someone with Coronavirus Disease 2019, COVID-19. Cases, or people with COVID-19, can be contagious 48 hours before they have symptoms, when they have symptoms, or even if they are not showing symptoms.
People experiencing homelessness are at increased risk for infection during community spread of COVID-19. This interim guidance includes recommendations for testing strategies and is intended to support response planning by shelters and homeless service providers in coordination with public health authorities and emergency management officials. Early and sustained action to slow the spread of COVID-19 will keep clients, staff, and volunteers healthy, and help shelters and homeless service providers maintain normal operations. It is intended for:
This guidance provides recommendations to prevent or slow the spread of COVID-19 in hotels, including hotels with fitness centers, gyms, and health clubs. These are precautions hotel managers and staff can take to protect the health and safety of guests and employees. The virus that causes COVID-19 can spread more easily than the seasonal flu and it appears COVID-19 disease is significantly more deadly than seasonal influenza.
The following can help prevent COVID-19, which is thought to spread mainly from person-to-person::
The COVID-19 outbreak may last for an extended period. The Illinois Department of Public Health has recommended community actions designed to keep people healthy, reduce exposures to COVID-19, and slow the spread of the disease. Local health department officials also have made recommendations appropriate to the COVID-19 situation in your community. Creating a household plan can help protect your health and the health of those you care about during the COVID-19 pandemic. The details of your household plan should be based on the needs and daily routine of your household members.
What should you do about work while you wait for test results?
- Please inform your supervisor at work that you have been tested for COVID-19 and note the date of testing.
- If you are experiencing symptoms: Notify your supervisor and stay home.
- If you are not experiencing symptoms: Request guidance from your supervisor on any potential work and patient care restrictions until you know your test results.
- Avoid using public transportation, rise-sharing, or taxis when commuting.
What should you do to protect yourself while you wait for test results?
- Wash your hands often with soap and water for at least 20 seconds. Clean your hands with an alcohol-based hand sanitizer that contains at least 60% alcohol if soap and water are not available.
- Avoid close contact with people who are sick.
- Avoid touching your eyes, nose, and mouth with unwashed hands.
This interim guidance addresses the use of COVID-19 antigen testing in long-term care (LTC) facilities and is aligned with guidance released by the Centers for Disease Control and Prevention (CDC). The U.S. Food and Drug Administration (FDA) has granted emergency use authorization to antigen point-of-care (POC) testing systems to detect the presence of SARS-CoV-2 viral protein.
This guidance addresses the use of point-of-care (POC) COVID-19 testing and screening in schools and other community settings. Four options are addressed by this SIREN: testing administered in school health-based clinics, testing onsite by other trained health care workers, testing provided in pharmacies, and POC testing in health care facilities. This guidance was originally released in conjunction with the state’s distribution of Abbott BinaxNOW tests to local health departments (LHDs), schools, and other settings. The BinaxNOW test is one of several antigen tests available and in use right now. More recently, IDPH entered a partnership with SHIELD Illinois to provide weekly testing to participating schools utilizing the SHIELD Illinois saliva-based RT-PCR testing. This guidance is also applicable to other types of U.S. Food and Drug Administration (FDA)-approved tests as described below.
The COVID-19 Equity Team’s Intimate Partner Violence and Child Abuse Prevention Workgroup has compiled this list of available resources for wide circulation and it will be updated as new information becomes available.
Intimate Partner/Domestic Violence Hotlines
Illinois Domestic Violence Hotline
(877) TO END DV or (877) 863-6338 (Voice)
(877) 863-6339 (TTY Hours: 24/7 /365)
Languages: Website available in English, Español, Arabic, Chinese, Dutch, French, German, Italian, Portuguese, Russian. For calls, the language line can accept calls in almost any language. Last year, they had calls in Arabic, Cantonese, Creole, English, Farsi, French, Gujurati, Hindi, Japanese, Korean, Lithuanian, Mandarin, Pashtu, Persian, Polish, Portuguese, Romanian, Russian, Serbian, Tagalog, Ukrainian, Urdu, Vietnamese, and others.
Different Forms of Contact: Phone call or text message
This guidance is intended to clarify guidance issued April 1, 2020 that may have caused confusion regarding the disclosure of COVID-19-positive persons to law enforcement and address questions that have been raised.
Guidance from the Illinois Attorney General
The Office of the Illinois Attorney General (OAG) was asked to address whether the Health Insurance Portability and Accountability Act (HIPAA) allows local health departments to provide information to law enforcement regarding individuals with positive tests for COVID-19. In response, on March 27, 2020, during a presentation to state’s attorneys, the OAG advised such disclosure is permissible because of a HIPAA exception. Specifically, the OAG affirmed the exception applies because “disclosure to first responders will enable them to use personal protective equipment (PPE) to reduce the risk of COVID-19 transmission.”
The Federal Government has begun a distribution program of a new antigen test: the Abbott BinaxNOW. The Abbott BinaxNOW test is a fast-acting antigen test granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to detect the presence of SARS-CoV-2 viral protein. The BinaxNOW test is administered through an anterior nares swab that is then inserted into a credit-card sized test, where a reagent is added. These tests are inexpensive, point-of-care (POC) tests, with results available within 15 minutes. This distribution program has two separate channels: